182 related articles for article (PubMed ID: 32330423)
61. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
[TBL] [Abstract][Full Text] [Related]
62. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
Green MR; Kihira S; Liu CL; Nair RV; Salari R; Gentles AJ; Irish J; Stehr H; Vicente-Dueñas C; Romero-Camarero I; Sanchez-Garcia I; Plevritis SK; Arber DA; Batzoglou S; Levy R; Alizadeh AA
Proc Natl Acad Sci U S A; 2015 Mar; 112(10):E1116-25. PubMed ID: 25713363
[TBL] [Abstract][Full Text] [Related]
63. The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation.
El-Sukkari D; Wilson NS; Hakansson K; Steptoe RJ; Grubb A; Shortman K; Villadangos JA
J Immunol; 2003 Nov; 171(10):5003-11. PubMed ID: 14607896
[TBL] [Abstract][Full Text] [Related]
64. Bm-CPI-2, a cystatin homolog secreted by the filarial parasite Brugia malayi, inhibits class II MHC-restricted antigen processing.
Manoury B; Gregory WF; Maizels RM; Watts C
Curr Biol; 2001 Mar; 11(6):447-51. PubMed ID: 11301256
[TBL] [Abstract][Full Text] [Related]
65. Therapeutic potential of targeting cathepsin S in pulmonary fibrosis.
Yoo Y; Choi E; Kim Y; Cha Y; Um E; Kim Y; Kim Y; Lee YS
Biomed Pharmacother; 2022 Jan; 145():112245. PubMed ID: 34772578
[TBL] [Abstract][Full Text] [Related]
66. Modulating mammary tumor growth, metastasis and immunosuppression by siRNA-induced MIF reduction in tumor microenvironment.
Zhang M; Yan L; Kim JA
Cancer Gene Ther; 2015 Oct; 22(10):463-74. PubMed ID: 26403072
[TBL] [Abstract][Full Text] [Related]
67. Proteases involved in MHC class II antigen presentation.
Villadangos JA; Bryant RA; Deussing J; Driessen C; Lennon-Duménil AM; Riese RJ; Roth W; Saftig P; Shi GP; Chapman HA; Peters C; Ploegh HL
Immunol Rev; 1999 Dec; 172():109-20. PubMed ID: 10631941
[TBL] [Abstract][Full Text] [Related]
68. Cathepsin S activity controls chronic stress-induced muscle atrophy and dysfunction in mice.
Wan Y; Piao L; Xu S; Meng X; Huang Z; Inoue A; Wang H; Yue X; Jin X; Nan Y; Shi GP; Murohara T; Umegaki H; Kuzuya M; Cheng XW
Cell Mol Life Sci; 2023 Aug; 80(9):254. PubMed ID: 37589754
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens.
Fujii H; Ivison SM; Shimizu H; Kajiwara R; Kariminia A; Yan M; Dutz JP; Schultz KR
Biol Blood Marrow Transplant; 2012 Apr; 18(4):546-56. PubMed ID: 22178962
[TBL] [Abstract][Full Text] [Related]
70. The p41 isoform of invariant chain is a chaperone for cathepsin L.
Lennon-Duménil AM; Roberts RA; Valentijn K; Driessen C; Overkleeft HS; Erickson A; Peters PJ; Bikoff E; Ploegh HL; Wolf Bryant P
EMBO J; 2001 Aug; 20(15):4055-64. PubMed ID: 11483509
[TBL] [Abstract][Full Text] [Related]
71. PU.1 regulates cathepsin S expression in professional APCs.
Wang Y; Baron RM; Zhu G; Joo M; Christman JW; Silverman ES; Perrella MA; Riese RJ; Cernadas M
J Immunol; 2006 Jan; 176(1):275-83. PubMed ID: 16365419
[TBL] [Abstract][Full Text] [Related]
72. Gallium arsenide modulates proteolytic cathepsin activities and antigen processing by macrophages.
Lewis TA; Hartmann CB; McCoy KL
J Immunol; 1998 Sep; 161(5):2151-7. PubMed ID: 9725206
[TBL] [Abstract][Full Text] [Related]
73. Glutathione depletion reveals impairment of antigen processing and inhibition of cathepsin activity by nitric oxide in antigen-presenting cells.
Lemaire G; Guittet O; Vesin MF; Lepoivre M; Cottet MH
Mol Immunol; 2009 Mar; 46(6):1100-8. PubMed ID: 19095306
[TBL] [Abstract][Full Text] [Related]
74. Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption.
Katunuma N; Matsunaga Y; Matsui A; Kakegawa H; Endo K; Inubushi T; Saibara T; Ohba Y; Kakiuchi T
Adv Enzyme Regul; 1998; 38():235-51. PubMed ID: 9762356
[TBL] [Abstract][Full Text] [Related]
75. Fibrosis in low-grade follicular lymphoma - a link to the TH2 immune reaction.
Lohneis P; Wienert S; Klauschen F; Anagnostopoulos I; Jöhrens K
Leuk Lymphoma; 2017 May; 58(5):1190-1196. PubMed ID: 27736316
[TBL] [Abstract][Full Text] [Related]
76. Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.
Zavasnik-Bergant V; Schweiger A; Bevec T; Golouh R; Turk V; Kos J
Immunology; 2004 Jul; 112(3):378-85. PubMed ID: 15196205
[TBL] [Abstract][Full Text] [Related]
77. The follicular lymphoma epigenome regulates its microenvironment.
Amin R; Braza MS
J Exp Clin Cancer Res; 2022 Jan; 41(1):21. PubMed ID: 35022084
[TBL] [Abstract][Full Text] [Related]
78. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
[TBL] [Abstract][Full Text] [Related]
79. Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages.
Hughes CS; Colhoun LM; Bains BK; Kilgour JD; Burden RE; Burrows JF; Lavelle EC; Gilmore BF; Scott CJ
Part Fibre Toxicol; 2016 Apr; 13():19. PubMed ID: 27108091
[TBL] [Abstract][Full Text] [Related]
80. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
